Xilis’ MicroOrganoSphereTM powers the only assay which can provide oncologists with accurate results of drug sensitivity on a patient’s own tumor within the clinical decision-making window -- finally realizing the promise of precision medicine. Xilis is developing a panel of disease specific assays systematically testing the most important standard-of-care drugs within equipoise or difficult-decision settings to help clinicians and their patients make the most appropriate treatment decision for their unique cancer in a timely manner.
The test is intended for use by qualified healthcare professionals in accordance with professional guidelines in oncology for previously diagnosed cancer patients, and is not conclusive or prescriptive for labeled use of any specific therapeutic product.
The Xilis test is currently in clinical trials for assessing advanced stage colorectal and breast cancer tumors as our lead candidates. Other tumor types and drug candidates are in development.